Company
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 4 of 15
"The period under review has been marked by significant progress across our various clinical and research programmes,” said Olav Hellebø, ReNeuron chief executive
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Data for the first time shows CTX could potentially produce non-donor-specific, 'off-the-shelf' stem cells as an alternative to existing treatments
Benjamin Yerxa, chief executive of the Foundation Fighting Blindness, said results from a recent clinical trial represented a major step forward for sufferers of a degenerative disease called retinitis pigmentosa
“Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,” the company said
A glance at some of the day's highlights from the Proactive Investors newswire
Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel have “world-class breadth of expertise” in the fields of ophthalmology and stem cell research, the company said
The venture will utilise ReNeuron's exosome-based drug delivery technology
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The stem cell specialist now has 40 patents worldwide
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Experienced biopharma director Nick Adams “will strengthen our business development capabilities and also be a dedicated resource for managing current and future licensing agreements”
Investments and investor services
The FTSE 250 went the other way and gained over 87 points on Friday
ReNeuron’s progress over the past year has been reflected in its share price, which has trebled since last March – the beginning of the company’s financial year
Investments and investor services
Footsie closed on Thursday nearly 21 points lower at 7,509.
Archive
The day ahead includes full-year results from Dart Group and US inflation data
Archive
Last month Kier issued a profit warning, so investors will be watching wearily as Thursday's trading update lands.
Archive
Aside from the two housebuilders, corporate updates in the coming week will also be delivered by retailers Ocado, Superdry and Dunelm
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
A look at some of the day's major movers, including Helical, Modern Water, Local Shopping REIT, Team17, TechFinancials, Westminster Group, Verditek and Pelatro
